A detailed history of Pro Share Advisors LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 60,453 shares of IBRX stock, worth $200,703. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,453
Previous 70,613 14.39%
Holding current value
$200,703
Previous $379,000 0.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.82 - $9.15 $48,971 - $92,964
-10,160 Reduced 14.39%
60,453 $382,000
Q1 2024

May 08, 2024

BUY
$3.23 - $6.17 $19,392 - $37,044
6,004 Added 9.29%
70,613 $379,000
Q4 2023

Feb 14, 2024

BUY
$1.25 - $5.21 $24,976 - $104,101
19,981 Added 44.77%
64,609 $324,000
Q3 2023

Nov 13, 2023

BUY
$1.29 - $3.1 $2,683 - $6,448
2,080 Added 4.89%
44,628 $75,000
Q2 2023

Aug 10, 2023

BUY
$1.53 - $6.41 $6,403 - $26,825
4,185 Added 10.91%
42,548 $118,000
Q1 2023

May 11, 2023

SELL
$1.35 - $4.78 $7,125 - $25,228
-5,278 Reduced 12.09%
38,363 $69,000
Q4 2022

Feb 02, 2023

BUY
$4.35 - $6.77 $4,106 - $6,390
944 Added 2.21%
43,641 $221,000
Q3 2022

Nov 04, 2022

BUY
$3.65 - $6.43 $9,161 - $16,139
2,510 Added 6.25%
42,697 $212,000
Q2 2022

Aug 01, 2022

SELL
$2.68 - $6.14 $37,530 - $85,984
-14,004 Reduced 25.84%
40,187 $150,000
Q1 2022

May 10, 2022

SELL
$5.05 - $7.53 $84,430 - $125,894
-16,719 Reduced 23.58%
54,191 $304,000
Q4 2021

Feb 08, 2022

SELL
$5.67 - $10.18 $121,360 - $217,892
-21,404 Reduced 23.19%
70,910 $431,000
Q3 2021

Nov 12, 2021

BUY
$9.17 - $14.24 $54,864 - $85,197
5,983 Added 6.93%
92,314 $899,000
Q2 2021

Aug 13, 2021

BUY
$13.41 - $22.4 $842,241 - $1.41 Million
62,807 Added 266.99%
86,331 $1.23 Million
Q1 2021

May 14, 2021

BUY
$12.83 - $42.25 $301,812 - $993,889
23,524 New
23,524 $558,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.33B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.